DA-9601 for erosive gastritis: Results of a double-blind placebo-controlled phase III clinical trial

Table 5 Incidence of adverse events (n, %)

	DA-9601 180 mg	Cetraxate 600 mg
Gastrointestinal
Dyspepsia	2 (1.08)	0
Nausea	2 (1.08)	0
Diarrhea	2 (1.08)	0
Heartburn	1 (0.54)	1 (0.54)
Abdominal pain	1 (0.54)	1 (0.54)
Acid reflux	0	1 (0.54)
Vomiting	1 (0.54)	1 (0.54)
CNS and ANS
Dizziness	1 (0.54)	0
Headache	1 (0.54)	1 (0.54)
Skin
Itching	1 (0.54)	1 (0.54)
Skin redness	1 (0.54)	1 (0.54)
Facial edema	0	1 (0.54)
Liver
sGPT elevation	1 (0.54)	1 (0.54)
sGOT elevation	0	1 (0.54)
Bilirubin elevation	0	1 (0.54)
Total	14 (7.53)	11 (5.91)